AbbVie Receives CHMP Positive Opinion for MAVIRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)* MAVIRET would also be an additional HCV treatment option for patients with specific tre... Biopharmaceuticals, Regulatory AbbVie, MAVIRET, glecaprevir, pibrentasvir, hepatitis C
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Hepatitis | Hepatitis C